RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Cash from financing

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$4B
P/E ratio
SummaryFinancials
Period EndCash from financing (Million USD)YoY (%)
Dec 31, 202497-262.04%
Dec 31, 2023-60-78.28%
Dec 31, 2022-276+100.34%
Dec 31, 2021-138-55.64%
Dec 31, 2020-311-35.99%
Dec 31, 2019-485-247.65%
Dec 31, 2018329-4467.74%
Dec 31, 2017-8-596.57%
Dec 31, 20162-81.88%
Dec 31, 20158-93.57%
Dec 31, 2014130-890.04%
Dec 31, 2013-16-520.28%
Dec 31, 20124-86.95%
Dec 31, 201130

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)